Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY (BMY)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Stada, Angelini among final bidders for $1 billion Bristol-Myers' UPSA unit - sources

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/08/2018 | 01:42pm EST
FILE PHOTO: The logo of Stada Arzneimittel AG is pictured at their headquarters in Bad Vilbel near Frankfurt

FRANKFURT/LONDON (Reuters) - German drugmaker Stada and Italian healthcare company Angelini are the only industry players to be shortlisted to make final bids for Bristol-Myers Squibb's French over-the-counter drugs business, four sources close to the deal said.

Two private equity firms, CVC Capital Partners and PAI Partners, have also made it through to the final round of the auction for UPSA, the maker of Dafalgan and Efferalgan painkillers, the sources told Reuters.

The sale, which is handled by Jefferies and Deutsche Bank, is worth about 1 billion euros (839.95 million pounds).

Bristol-Myers Squibb (BMS), Stada, CVC and PAI declined to comment while Angelini was not immediately available for comment.

BMS has given bidders a deadline of late November to submit final proposals, the sources said.

The U.S. firm took full control of the unit, which also produces effervescent aspirin and vitamin C, 24 years ago.

It is now looking to concentrate on high-margin prescription drugs, particularly for cancer, and hopes to sell UPSA for a multiple of 7.5 to 8 times its core earnings of 120 million-130 million euros, the sources said.

Germany's Stada, which is backed by private equity firms Bain Capital and Cinven, is widely seen as the frontrunner for the deal as it seeks to build scale through major acquisitions, the sources said.

Italy's Angelini, which is advised by BNP Paribas, is also willing to embark on a big deal, two of the sources said.

The sale initially drew interest from other big industry players including U.S.-run drugmaker Mylan NV and Japanese healthcare firm Taisho Pharmaceutical which subsequently walked away from the process, the sources said.

UPSA generated revenue of 425 million euros in 2017 and employs about 1,500 people in France.

The sale comes amid a series of high-profile deals in the consumer health industry including Procter & Gamble's acquisition of Merck KGaA's vitamin brands in April and GlaxoSmithKline deal to buy Novartis out of their consumer healthcare joint venture for $13 billion.

(Reporting by Arno Schuetze in Frankfurt and Pamela Barbaglia in London; Additional reporting by Stephen Jewkes in Milan and Matthias Blamont in Paris; Editing by Edmund Blair)

By Arno Schuetze and Pamela Barbaglia

Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY -0.38% 49.5 Delayed Quote.-7.71%
GLAXOSMITHKLINE -1.60% 1484.4 Delayed Quote.1.17%
MYLAN NV 0.12% 29.37 Delayed Quote.7.12%
NOVARTIS 0.41% 87.38 Delayed Quote.3.55%
PROCTER & GAMBLE COMPANY -0.67% 91.39 Delayed Quote.0.10%
STADA ARZNEIMITTEL 0.00%-End-of-day quote.-8.87%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB COMPA
04:18aBRISTOL-MYERS SQUIBB COMPANY : - European Commission Approves Opdivo Plus Low-Do..
AQ
01/15MSKCC says senior execs may not hold industry board seats
AQ
01/15Ascletis to develop Alphamab's PD-L1 antibody for HBV in China
AQ
01/14BRISTOL MYERS SQUIBB : EC Approves Opdivo Plus Yervoy for Some Patients with Ren..
DJ
01/14BRISTOL MYERS SQUIBB : European Commission Approves Opdivo (nivolumab) Plus Low-..
PU
01/12BRISTOL MYERS SQUIBB : Computational scientists design a new IL-2 cancer drug an..
AQ
01/10ONO PHARMACEUTICAL : Opdivo meets OS endpoint in esophageal cancer trial
AQ
01/08GlaxoSmithKline to look for early-stage assets - CEO
RE
01/08CELGENE INVESTOR ALERT BY THE FORMER : Kahn Swick & Foti, LLC Investigates Adequ..
PR
01/08SECOND BIG M&A DEAL OF 2019 : Lilly to acquire Loxo
AQ
More news
Financials ($)
Sales 2018 22 548 M
EBIT 2018 6 169 M
Net income 2018 5 190 M
Finance 2018 1 244 M
Yield 2018 3,42%
P/E ratio 2018 15,20
P/E ratio 2019 14,11
EV / Sales 2018 3,42x
EV / Sales 2019 3,09x
Capitalization 78 297 M
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 58,3 $
Spread / Average Target 21%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Johanna Mercier President & Head-US Commercial
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY-7.71%78 297
JOHNSON & JOHNSON-0.60%344 044
PFIZER-2.93%245 746
NOVARTIS3.55%221 313
ROCHE HOLDING LTD.5.59%220 097
MERCK AND COMPANY-2.50%190 790